Literature DB >> 3729336

Effects of selenazofurin and ribavirin and their 5'-triphosphates on replicative functions of influenza A and B viruses.

S K Wray, R H Smith, B E Gilbert, V Knight.   

Abstract

We studied the effects of selenazofurin alone and in combination with ribavirin on replication of influenza A and B viruses. These drugs showed little cytotoxicity as measured by leucine incorporation into protein in MDCK cells, although they were potent inhibitors of viral replication in the same cells. Selenazofurin inhibited growth of influenza A and B viruses at concentrations (50% inhibitory dose = 25 and 19 microM, respectively) which were similar to those at which growth was inhibited by ribavirin (50% inhibitory dose = 50 and 30 microM, respectively). The inhibition of replication of either influenza A or B virus was additive for any combination of ribavirin and selenazofurin. The effects of the 5'-triphosphate of selenazofurin on two replicative functions associated with the influenza virus RNA-dependent RNA polymerases, primer generation (initiation of transcription) and its subsequent elongation, were measured. Elongation was more sensitive to selenazofurin 5'-triphosphate than was primer generation, and the effects of this drug on these functions were approximately the same as those of ribavirin 5'-triphosphate. The activities of ribavirin triphosphate and selenazofurin triphosphate were additive, and combinations did not potentiate the individual inhibitory effects of these drugs on elongation.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3729336      PMCID: PMC180366          DOI: 10.1128/AAC.29.1.67

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  17 in total

1.  Metabolism of 5-amino-1-beta-D-ribofuranosylimidazole-4-carboxamide and related five-membered heterocycles to 5'-triphosphates in human blood and L5178Y cells.

Authors:  T P Zimmerman; R D Deeprose
Journal:  Biochem Pharmacol       Date:  1978-03-01       Impact factor: 5.858

2.  Inhibition of influenza virus ribonucleic acid polymerase by ribavirin triphosphate.

Authors:  B Eriksson; E Helgstrand; N G Johansson; A Larsson; A Misiorny; J O Norén; L Philipson; K Stenberg; G Stening; S Stridh; B Oberg
Journal:  Antimicrob Agents Chemother       Date:  1977-06       Impact factor: 5.191

3.  Future influenza vaccines and the use of genetic recombinants.

Authors:  E D Kilbourne
Journal:  Bull World Health Organ       Date:  1969       Impact factor: 9.408

4.  In situ detection of mycoplasma contamination in cell cultures by fluorescent Hoechst 33258 stain.

Authors:  T R Chen
Journal:  Exp Cell Res       Date:  1977-02       Impact factor: 3.905

5.  A method for testing for synergy with any number of agents.

Authors:  M C Berenbaum
Journal:  J Infect Dis       Date:  1978-02       Impact factor: 5.226

6.  Mechanism of action of 1- -D-ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent.

Authors:  D G Streeter; J T Witkowski; G P Khare; R W Sidwell; R J Bauer; R K Robins; L N Simon
Journal:  Proc Natl Acad Sci U S A       Date:  1973-04       Impact factor: 11.205

7.  Synergistic antiviral effects of ribavirin and the C-nucleoside analogs tiazofurin and selenazofurin against togaviruses, bunyaviruses, and arenaviruses.

Authors:  J W Huggins; R K Robins; P G Canonico
Journal:  Antimicrob Agents Chemother       Date:  1984-10       Impact factor: 5.191

8.  Effect of ribavirin triphosphate on primer generation and elongation during influenza virus transcription in vitro.

Authors:  S K Wray; B E Gilbert; V Knight
Journal:  Antiviral Res       Date:  1985-02       Impact factor: 5.970

9.  Broad-spectrum synergistic antiviral activity of selenazofurin and ribavirin.

Authors:  J J Kirsi; P A McKernan; N J Burns; J A North; B K Murray; R K Robins
Journal:  Antimicrob Agents Chemother       Date:  1984-10       Impact factor: 5.191

10.  A unique cap(m7GpppXm)-dependent influenza virion endonuclease cleaves capped RNAs to generate the primers that initiate viral RNA transcription.

Authors:  S J Plotch; M Bouloy; I Ulmanen; R M Krug
Journal:  Cell       Date:  1981-03       Impact factor: 41.582

View more
  4 in total

1.  Inhibitory effect of a nucleotide analog on infectious salmon anemia virus infection.

Authors:  Andrea Rivas-Aravena; Eva Vallejos-Vidal; Marcelo Cortez-San Martin; Felipe Reyes-Lopez; Mario Tello; Patricia Mora; Ana María Sandino; Eugenio Spencer
Journal:  J Virol       Date:  2011-06-08       Impact factor: 5.103

2.  Comparative activities of several nucleoside analogs against influenza A, B, and C viruses in vitro.

Authors:  S Shigeta; K Konno; T Yokota; K Nakamura; E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1988-06       Impact factor: 5.191

3.  Dimroth rearrangement-based synthesis of novel derivatives of [1,3]selenazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidine as a new class of selenium-containing heterocyclic architecture.

Authors:  Seddigheh Sheikhi-Mohammareh; Ali Shiri; Joel Mague
Journal:  Mol Divers       Date:  2021-03-15       Impact factor: 2.943

Review 4.  Antiviral chemotherapy and prophylaxis of viral respiratory disease.

Authors:  S J Sperber; F G Hayden
Journal:  Clin Lab Med       Date:  1987-12       Impact factor: 1.935

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.